Build **LabIQ AI**—a $45K/year **Healthtech SaaS + wetware platform** that **enables ‘AI-driven lab automation for non-PhDs’**, democratizing scientific research. The platform would: (1) **Deploy ‘LabBench’**: $15K/unit modular robotic workstations (e.g., Opentrons OT-2) with **edge AI (Jetson Orin)** to automate experiments (e.g., ‘Run CRISPR screen—no PhD required’); (2) **Provide ‘ProtocolIQ’**: AI-generated SOPs for lab tasks (e.g., ‘ELISA assay: Follow SOP #45—98% success rate’); (3) **Integrate with ‘Biotech APIs’** (e.g., Benchling, Twist Bioscience) to auto-order reagents (e.g., ‘CRISPR kit: Auto-reorder—stock low’); (4) **Offer ‘Clinical Trial Optimizer’**: AI-driven recruitment + protocol design (e.g., ‘Trial #XYZ: 30% faster enrollment—adjust cohort’); (5) **Include ‘Carbon-Aware Lab’**: Optimize experiments for renewable energy (e.g., ‘Run assay at 2AM—grid 100% wind’).

{"sufferingParties":["Research universities","biotech/pharma companies","government labs","patients awaiting treatments"],"currentSystemBroken":"Declining PhD admissions create a bottleneck in scientific R&D, especially in drug discovery (e.g., CRISPR, mRNA) and climate tech (e.g., carbon capture). Universities cite funding cuts, while industry struggles to fill roles. The gap is widening: 40% of biotech startups report delays due to talent shortages.","financialOperationalCost":"NIH funding cuts cost $2B/year in stalled research. Biotech startups delay clinical trials (avg. $1.3M/month per trial), and climate tech projects (e.g., DAC) face 12-18 month delays."}